Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
On March 18 2014 it closed at it's all time high of $121.50 o_O
Yes, to quote Adam Feuerstein:
'Bad clinical trials produce bad data, and Anavex is conducting a garbage study.'
SMH
Did you see Tobira's stock price back in 2014?
I thought for a moment you meant Seeking Alpha hehe. What was I thinking :)
Ziggy apologised and your input is appreciated by the majority here. Waiting for your next post.
RVT-101, originally called SB-742457, had been a GlaxoSmithKline product for years. After 13 disappointing clinical trials, management decided to sell the drug to AXON for $5 million in December 2014. The AXON IPO seven months later turned into an ideal mob scene for a Cecil DeMille epic, as that $5 million magically exploded into a $3 billion valuation in minutes.
13 clinical failures. Wow.
I called IR yesterday and asked about this conference and if we could expect something about Parkinson's maybe. IR said that Anavex will attend the conference but will not be presenting. I kind of felt they are holding back the reason why Anavex is going to be there, perhaps we will get a surprise announcement? 'It is what it is' I was told. Fingers crossed.
Tell them you're Christopher Missling from Anavex and want to speak to the chief. Gauging their reaction could tell you something :)
Just joking.
Seems that skepticism never existed for AXON then, trading at $17.
Anavex may have short lines with Takeda..
Steffen Thomas, PhD
Steffen Thomas, PhD, a director of Anavex, has over 15 years of experience as a European patent attorney and is currently practicing at Epping Hermann Fischer, a major intellectual property law firm in Europe. Previously, he worked for Japan-based Takeda Pharmaceutical Company, the largest pharmaceutical company in Asia and a top firm worldwide, as an in-house patent attorney.
They are now planning the Phase 2/3 study, which will be a larger trial. If you look at the corporate presentation Spring 2016 on Anavex's website, you will see this one is checked on slide 32.
I don't know.
Hi Powerwalker, I called Christine and she said Primoris is still representing Anavex, alongside Rivereast Investors Relations. So apparantly Anavex is having 2 IR's at this time. She told me the same things as Peasan8 pointed out on Yahoo. Alzheimer Phase 3 preparations are being made and the same goes for Rett's Phase 2. No imminent dilution, just a shelf in place for future raises when Anavex deems necessary.
What about the HAM-D scores?
You may be right, but have you compared Donepezil's safety profile with Anavex's A2-73 yet? Don't you think A2-73 slightly outperforms the SOC already?
Well the reality is, the best companies don't toot their horns every week, releasing fluff PR's.
If you know what you own and have patience, it shouldn't bother you. I'm in it for the long run and plan to buy some more. Whining is not for me.
Hey, if you have questions call IR: Christine # 1-866-505-2895
She will be happy to answer all your questions.
I think near-term dilution is not something we have to worry about.
From Peasan8 on Yahoo board who got a response from IR today:
I am quoting: "NO DILUTION"!
The company is continuing with the research...moving forward with the different trials, phase 2a....Rett...CNS...PK...
IR said that they filed the S3 just to have it for a "shelf file". They have PLENTY of money for the next 12 months....no worries here.
Dr. Missling is AWARE of what is going on with stock price. ANAVEX very excited and continues to focus on science not the foolish articles.
Would like to see actual data (post 06/30/2016). How much time is left for all filings to be reported?
Have you seen how many hit pieces were written in the last 12 months? Blatant (non-scientific) attacks and a bogus lawsuit for this little company. You think Anavex received fair exposure? So much for Wall Street.
All his Anavex articles are accessible on his site drkkd.com under Archives --> SA Archive. To read them you have to register (free).
Interesting article on Michael J. Fox Foundation, displaying their influence and stature.
https://www.statnews.com/2016/08/30/parkinsons-study-fox-foundation-feud/
Hopefully Anavex gets some serious funding from them!
You're welcome Bas. They know about Anavex, see link below:
http://mitochondrialdiseases.org/anavex-2-73-linking-mitochondrial-functionality-to-alzheimers/
That's a lot of money for yet another future amyloid plaque removal fiasco.
'The company licensed its investigational drug, crenezumab, to Roche a decade ago to target protein plaques found in brains of patients with Alzheimer's disease. The drug has now moved into late-stage trials.'
Recent paid pumping Kund? Please elaborate.
Here's a nice site with an overview of CNS diseases Anavex may be able to treat:
http://mitochondrialdiseases.org/related-diseases/
Anavex 2-73 gets a special mention too.
Tell us something we don't know already.
One can always dream of a Alz Phase 3 announcement with partnership. Or a multimillion government grant. Or a paid for Rett trial announcement. Or a Parkinson trial. You think no news will come at all before the end of the year?
For every seller there is a BUYER. Now who would those buyers be..
The big boys want in cheap. Always been that way.
Someone from the Yahoo board contacted IR.
Response this AM: "Anavex has over a year's worth of cash and no current plans to raise money, especially at the current share price".
If there is no dilution, I think this is a shake out before good news to scare and get rid of retail investors. Looking for a strong surge soon.
I looked at the data again, looks good to me overall.
http://www.anavex.com/wp-content/uploads/2016-07-27_Poster_AVXL_Wednesday_AAIC_July_2016_Final.pdf
If people wanna call this mediocre or bad data, I challenge them to name a drug that gives equal or better results.
AVXL holding up nicely today in a sea of red. I really think this is the bottom here.
Here's the AVXL hit piece that was removed:
http://www.ijournal.com/article.php?feedCategoryId=1&countryId=1&a=36308464&articleTitle=Anavex_Hidden_Debt_Gives_Heightened_Urgency_To_Equity_Raise
LOL Short author's article pulled from Valuewalk
http://www.valuewalk.com/2016/09/anavex-clarification/
They keep trying..
Too bad it doesn't do any more than remove amyloid plaques. No cognitive improvement and risk of brain swelling.
Morningstar funds & institutional ownership shows some new and increased holdings including Merrill Lynch & Co Inc:
100,616 shares, 8,563.06 % increase, date 06/30/2016
Not bad.
http://investors.morningstar.com/ownership/shareholders-buying.html?t=AVXL®ion=usa&culture=en-US&ownerCountry=USA
And Cory Renauer believes that Anavex needs to spend millions on their own lab pfff.
The Alzheimer Association is well aware of Anavex, I contacted them a while ago and this was their reply:
To whom it may concern,
Thanks for contacting the Alzheimer's Association. We do offer research grants for clinical trial studies. If Dr. Macfarlane is successful with his phase IIa trial, he can certainly apply for one of our research grants to help fund a phase III study.
Like you, we look forward to the development of a true cure for Alzheimer's disease. Thanks again for your email.
Best,
Science Staff
Alzheimer's Association